Skip to main content
. 2021 Sep 11;297(4):101191. doi: 10.1016/j.jbc.2021.101191

Figure 4.

Figure 4

Effects of A-443654 in 3XSNCA fibroblasts.A, relative levels of α-synuclein protein in fibroblasts from patients with no pathology (normal), PD (3XSNCA, GBA mutation, LRKK2 mutation), parkinsonism (GBA mutation), or Gaucher’s disease (GBA mutation) quantified by ELISA. B, ELISA of α-synuclein levels in 3XSNCA fibroblasts treated with increasing doses of A-443654 for 48 h. C, viability of 3XSNCA fibroblasts treated with increasing doses of A-443654 for 48 h by MTT. D, western blot analysis of α-synuclein in normal and 3XSNCA fibroblasts (left) and quantification of trimers from three independent experiments (graph, right). E, qPCR quantification of SNCA mRNA levels in normal and 3XSNCA fibroblasts. ∗p < 0.05; ∗∗p < 0.01; ns, not significant. Student’s t test with Bonferroni correction.